Whether it’s a bull or bear market, TrendingWallStreet has you covered. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get exclusive access to our free stock reports.
Facebook, Inc. (NASDAQ: FB) shares closed up 4.81 percent on Monday with nearly 100 million shares traded. The stock was one of the most active stocks on the NASDAQ and also hit a new 52-week high of $58.32 during intra-day trading. Facebook’s share price has more than doubled this year. Research firm EMarketer says both Facebook and Twitter will expand their share of the digital ad market. By 2015, Facebook will snag 9%, up from 5.9% in 2012, EMarketer projects.
Get more information on Facebook, Inc. and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/FB
Michael Kors Holdings Limited (NYSE: KORS) shares closed down 3.67 percent on about 10.2 million shares traded. The stock was one of the most active stocks in the NASDAQ. The stock was among many retailers reacting to economic data. Economic data released in the morning indicated that consumer spending rose 0.5% in November after jumping by 0.4% in October when compared to the previous month. Additionally, consumer income rose 0.2% in November after falling 0.1% in October.
Get more information on Michael Kors Holdings Limited and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/KORS
Nutranomics Inc. (OTCBB: NNRX) shares closed down 9.09 percent on Monday with nearly 1 million shares traded. The stock was one of the biggest decliners in the OTCBB market. On December 19th, the company announced that it had received a product reorder from Buildmore Enterprise Co, Ltd. ("Buildmore"), a health food supplement contract manufacturing and distribution company located in Taipei City, Taiwan.
Get more information on Nutranomics Inc. and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/NNRX
Provectus Pharmaceuticals, Inc. (OTC: PVCT) shares closed up 22.67 percent on Monday with about 2.6 million shares traded. The stock was one of the biggest gainers in the OTC market and hit a new 52-week high of $1.85 during intra-day trading. The company held a Type C meeting with the FDA’s Division of Oncology Products 2 on December 16, 2013. The purpose of the meeting was to determine which of the available paths that Provectus’ novel oncology drug PV-10 will take in pursuit of FDA approval and commercialization.
Get more information on Provectus Pharmaceuticals, Inc. and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/PVCT
Disclosure: TrendingWallStreet.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.